MARKET

ANNX

ANNX

Annexon, Inc.
NASDAQ
5.26
-0.07
-1.31%
After Hours: 5.15 -0.11 -2.04% 19:08 08/13 EDT
OPEN
5.36
PREV CLOSE
5.33
HIGH
5.40
LOW
5.20
VOLUME
3.12M
TURNOVER
--
52 WEEK HIGH
7.18
52 WEEK LOW
2.030
MARKET CAP
861.81M
P/E (TTM)
-4.3274
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Humacyte (HUMA) and TScan Therapeutics (TCRX)
TipRanks · 8h ago
Annexon Raised to Market Perform From Market Underperform by Citizens
Dow Jones · 9h ago
Citizens Upgrades Annexon to Market Perform
Benzinga · 9h ago
Analyst Reiterates Buy on Annexon, Maintains $14 Price Target on Favorable ARCHER II Phase 3 Design
TipRanks · 10h ago
Annexon Biosciences (ANNX) Gets a Buy from Wells Fargo
TipRanks · 12h ago
Analyst Reiterates Buy on Enhanced GA Strategy and GBS Upside, Maintaining $8 Price Target
TipRanks · 12h ago
Annexon: Strategic Phase 3 Trial Flexibility Supports Buy Rating and Unchanged $25 Price Target
TipRanks · 1d ago
Annexon Advances C1q-Targeted Therapies; Tanruprubart BLA Filing And ARCHER II Data On The Horizon
NASDAQ · 1d ago
More
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. It identifies and characterizes the role of the classical complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology, using its proprietary platform. Its lead candidate, ANX005, an investigational, full-length monoclonal antibody (mAb), is formulated for intravenous administration as the potential first targeted treatment for patients with Guillain-Barre Syndrome (GBS). It is advancing ANX1502, a novel small-molecule inhibitor of classical complement designed for oral administration in a range of chronic autoimmune diseases. It is also advancing ANX007, designed to block C1q locally in the eye, to provide complete protection against excess classical complement activity and the loss of photoreceptor neurons.

Webull offers Annexon Inc stock information, including NASDAQ: ANNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANNX stock methods without spending real money on the virtual paper trading platform.